Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
May 1st, 2007
ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) announced that results of studies of the mechanism of ProLindac's anticancer activity will be presented today at the American Association for Cancer Research (AACR) 2007 annual meeting in Los Angeles at the Los Angeles Convention Center. The two poster presentations describe preclinical studies performed by Access collaborators at two prominent institutes in France. "We are delighted to have two ProLindac poster presentations at one of the most prestigious scientific conferences in cancer," stated David P. Nowotnik, Access' Senior Vice President, Research and Development. "The presentations reaffirm ProLindac's...
Source: Cancer Weekly (2007-05-01)
|
